Last reviewed · How we verify
Nifedipine GITS
Nifedipine GITS is a long-acting calcium channel blocker that reduces calcium influx into vascular smooth muscle cells, causing vasodilation and lowering blood pressure.
Nifedipine GITS is a long-acting calcium channel blocker that reduces calcium influx into vascular smooth muscle cells, causing vasodilation and lowering blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Nifedipine GITS |
|---|---|
| Also known as | Adalat |
| Sponsor | Peking University First Hospital |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nifedipine blocks L-type calcium channels in the cell membrane, preventing calcium entry into vascular smooth muscle and cardiac cells. This reduces intracellular calcium concentration, leading to relaxation of vascular smooth muscle and decreased peripheral vascular resistance. The GITS (Gastrointestinal Therapeutic System) formulation provides sustained release over 24 hours, enabling once-daily dosing for improved patient compliance in hypertension management.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Headache
- Peripheral edema
- Flushing
- Dizziness
- Palpitations
Key clinical trials
- Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness (PHASE4)
- REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial (PHASE4)
- Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study
- Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects (PHASE1)
- Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension (PHASE4)
- Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension (PHASE3)
- Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy. (PHASE4)
- Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifedipine GITS CI brief — competitive landscape report
- Nifedipine GITS updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI